Funding to support primary care residents in rural and underserved communities

February 16, 2022 – Earlier this month, the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), announced the availability of $19.2 million in American Rescue Plan funding to support and expand community-based primary care residency programs. Awardees will use this funding to train residents to provide quality care to diverse populations and communities, particularly in underserved and rural areas.  

The Teaching Health Center Graduate Medical Education (THCGME) program supports training in community-based care settings. These training sites offer primary care and dental residents experience working with diverse, high-need patient communities in areas that often lack sufficient primary care physicians and dentists, according to a release. After completing residencies, the majority of THCGME program graduates will continue to practice in underserved or rural settings and two-thirds continue to practice primary care – nearly double the average of all medical and dental graduates. 

“Training physician and dental residents in community settings is helping us to build a stronger primary care workforce that better supports the communities served,” said HRSA Administrator Carole Johnson. “The American Rescue Plan funding announced today will help us to grow the number of primary care residents training and practicing in underserved communities, a critical step toward expanding access to high-quality health care and advancing health equity.” 

This THCGME funding opportunity will increase the program’s reach and support the equivalent of approximately 120 full-time resident positions. Teaching Health Center primary care residency programs offer training in skills needed to care for populations such as members of tribal communities, residents of rural areas, and people who are medically underserved. 

Funding to support primary care residents in rural and underserved communities – The Journal of Healthcare Contracting (jhconline.com)

Owens & Minor, Inc. Signs Definitive Agreement to Acquire Apria, Inc.

January 10, 2022 – Owens & Minor, Inc. (Owens & Minor) and Apria, Inc. (Apria) announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. 

“I’m very excited about the acquisition of Apria, which will strengthen our total company value proposition. The combination of two complementary businesses in Byram Healthcare and Apria will enable us to better serve the entire patient journey – through the hospital and into the home – ultimately furthering our mission of Empowering Our Customers to Advance Healthcare,” said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor. “In addition, this transaction diversifies our total company revenue stream by expanding our presence in the higher-growth home healthcare market.” 

“I am energized and enthusiastic to join Owens & Minor,” said Dan Starck, Chief Executive Officer of Apria. “Both companies share cultures fueled by a commitment to customers, patients, teammates and the communities we serve. We look forward to joining together and delivering the highest quality healthcare solutions to our customers.” 

Owen & Minor’s Strategic Rationale

  • Strengthens total company value proposition, enables Owens & Minor to better serve the entire patient journey and positions Owens & Minor as a leader in the home healthcare market. The transaction builds upon Owens & Minor’s strong capabilities in product manufacturing and healthcare services. 
  • Accelerates growth and diversifies revenue base by expanding Owens & Minor’s presence in the higher-growth home healthcare market. 
  • Accretive to revenue, adjusted EBITDA, adjusted earnings per share, and enhances the free cash flow generation, enabling Owens & Minor to rapidly deleverage while continuing to invest across the business. 
  • Expands the Patient Direct platform with access to over 90 percent of insured healthcare customers in the U.S. 
  • Broadens the Patient Direct product portfolio by combining our strength in diabetes, ostomy, incontinence, and wound care, with Apria’s product portfolio strength in home respiratory, obstructive sleep apnea, and negative pressure wound therapy. These product portfolios are complementary and do not overlap as many of these products are needed to treat the same and multiple chronic and acute conditions. 
  • Increases the attractiveness to Payors, Providers, and Patients due to the broader product portfolio, combined with our scale, geographic footprint, and delivery model. 
  • Creates a platform for future growth within this highly fragmented and growing space, with an approximate $50 billion total addressable market. 
  • Enables the acceleration of support for the hospital customers seeking to expand into home healthcare delivery. 

Learn More 

Filed Under: Repertoire’s Dail-eNews

Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins therapy market

Increases capabilities serving the high growth cell and gene therapy market

WALTHAM, Mass., Jan. 5, 2022 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion.

Based in Cranbury, New Jersey, PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models. PeproTech’s recombinant proteins portfolio complements Thermo Fisher’s cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering.

“PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “In combination with our proprietary bioprocessing and cell culture technologies, this complementary transaction positions us to partner with our customers to drive the evolution of the fast-growing market for cell and gene therapies. By leveraging our commercial reach, we will be able to efficiently grow the PeproTech business and generate attractive financial results all while furthering our Mission to enable our customers to make the world healthier, cleaner and safer.”

Casper added, “With more than three decades of experience across a broad range of applications for drug development and therapeutic products, the PeproTech team has built long-standing customer relationships in pharma and biotech and life sciences research. We look forward to welcoming their incredibly talented team to Thermo Fisher.”

Bob Goldman, president and co-founder of PeproTech, commented, “We are pleased to join Thermo Fisher given their team’s outstanding industry leadership and shared commitment to develop innovative therapies that improve patient outcomes. PeproTech’s reputation for unparalleled product consistency and quality directly aligns with that of Thermo Fisher’s, and we look forward to building on our success as part of the world leader in serving science.”

PeproTech will become part of the biosciences business within Thermo Fisher and will be integrated into the Life Sciences Solutions Segment.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team of more than 100,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

About PeproTech

PeproTech, Inc., a New Jersey corporation that was incorporated in 1988, creates the building blocks of life science research by manufacturing high-quality products that advance scientific discovery and human health. Our business is heavily weighted towards the development, manufacture and sale of research-use only and GMP cytokines and other products that support and address the needs and demands of today’s scientists and researchers.

Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

SOURCE Thermo Fisher Scientific

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.

Health systems suspend vaccine mandate after CMS suspends ruling

December 7, 2021 – CMS in a Dec. 2 memorandum suspended implementation and enforcement of its COVID-19 vaccination mandate for healthcare workers after judges in Missouri and Louisiana issued preliminary injunctions temporarily halting the start of the COVID-19 vaccination mandate.

An injunction issued Nov. 30 by a federal judge in Louisiana temporarily blocks CMS from enforcing its vaccination mandate for healthcare workers until legal challenges are resolved.

The injunction effectively expanded a separate order issued Nov. 29 by a federal judge in Missouri that temporarily halted the mandate in 10 states.

In light of the legal challenges, hospitals and health systems have made new decisions, including suspending their requirements.

Since the announcement, several healthcare organizations have announced they are suspending their mandates or extending the deadlines for employees. Here are a few:

  • AdventHealth announced Dec. 2 that it was suspending all vaccination requirements of it’s COVID-19 vaccination policy. The health system is still requiring employees to declare their COVID-19 vaccination status with their medical staff office.
  • HCA announced on Dec. 1 that the organization would “pause the COVID-19 vaccine requirement for all Medical City Healthcare colleagues.”
  • Cleveland Clinic announced Dec. 2 that it is pausing the implementation of the health system’s vaccination policy, which required employees and those who provide services with the health system to receive the vaccine or an approved exemption with accommodations. The health system said it will have additional safety requirements for unvaccinated workers, including periodic testing for those providing direct clinical care. 
  • Tenet Healthcare (Dallas, TX) also said it will not enforce the CMS vaccination requirement for individuals working in its facilities. Tenet said workers who are in a state that has previously issued a vaccination mandate must continue to follow the state or local requirement.
  • Hospital Sisters Health System (Springfield, IL) announced Dec. 3 that it is keeping its newly established vaccination policy in place while courts review the federal rule for healthcare workers. The health system is extending the vaccination deadline from Dec. 6 to Jan. 31.
  • Kootenai Health (Coeur d’Alene, ID) is also delaying the effective date of its vaccination requirement from Dec. 6 to Dec. 13

Health systems suspend vaccine mandate after CMS suspends ruling – The Journal of Healthcare Contracting (jhconline.com)

As Many as 1.6 Million Americans Lost Sense of Smell Due to COVID-

THURSDAY, Nov. 18, 2021 (HealthDay News)

Stern, 47, a New York City author and mother, has seen countless doctors and taken many types of medicine, vitamins and supplements to get her sense of smell back. She also undergoes acupuncture regularly and saw an energy healer — all to no or very little avail.

“Yesterday, my husband asked ‘what’s that smell?’ and I had no idea,” Stern recalled. “It was eggs boiling over in the kitchen that almost caught fire.”

Unfortunately, she’s not alone. As many as 1.6 million people in the United States will develop olfactory dysfunction or loss of smell from COVID-19, a new study projects. Some, like Stern, develop chronic dysfunction that lasts for six months or more.

“Given the surge in acute COVID-19 infections last fall and winter and the ongoing cases, there is a pending tidal wave of new cases of chronic olfactory dysfunction that deserves our attention,” said study author Dr. Jay Piccirillo, a professor of otolaryngology—head and neck surgery at Washington University School of Medicine in St. Louis. “We have to try to figure out what to do for these people, and the sad news is that we don’t have any effective treatments for chronic COVID-19-related loss of smell yet.”

Without the ability to smell, you can’t taste food or detect harmful odors such as gas and smoke. Like Stern, many people with chronic loss of sense of smell report a poorer quality of life, and feelings of depression as well.

Exactly how COVID-19 can rob you of your ability to smell isn’t fully understood yet, but many viral illnesses cause similar symptoms.

“We think that the virus attacks the supporting cells in the nose that help olfactory nerves do their job,” Piccirillo said. Olfactory nerves are responsible for our sense of smell.

To get a better sense of how many people will lose their sense of smell due to COVID, the researchers culled data on new daily U.S. COVID cases, frequency of loss of smell, and rates of recovery.

Based on these numbers, they estimate that more than 700,000 — and possibly as many as 1.6 million — Americans will have chronic loss of smell due to COVID-19. The actual number may be even higher as the data included only state-reported positive cases, and not all COVID cases get reported.

Once supporting cells in the nose recover, smell returns for about 90% of people with COVID, Piccirillo said. Researchers still aren’t sure why some people, like Stern, experience chronic loss of smell.

“People whose supporting cells get more infected and had a heavier load of the virus are more likely to have persistent loss of smell,” Piccirillo said.

The findings were published Nov. 18 in JAMA Otolaryngology–Head & Neck Surgery.

Meanwhile, the phones have been ringing off the hook at the Smell & Taste Treatment and Research Foundation in Chicago due to the growing numbers of people with chronic loss of smell from COVID, said Dr. Alan Hirsch, its neurological director.

“There is no U.S. Food and Drug Administration-approved drug for smell and taste loss from COVID-19,” said Hirsch, who reviewed the findings. “Instead, doctors will try medications and supplements that have shown to be effective in other virus-related smell and taste deficits.”

Other causes of loss of smell include age, smoking and certain neurologic diseases such as Parkinson’s or Alzheimer’s, Hirsch said. These come on slowly, and many people don’t notice or complain. COVID-related loss of smell comes on quickly.

People with COVID-related loss of smell are younger than those who are affected by other causes of olfactory dysfunction and will have to live with this troublesome symptom much longer as a result, he said.

“We will continue to see more cases of COVID-19-related loss of smell and as people age, this will be added on to age deficits to make the loss that much more pronounced,” Hirsch said.

If it’s been more than a month since you recovered from COVID-19 and you still can’t smell, you should see a specialist to learn if there is more you can do to recover it, he suggested.

“Food and danger are important things to smell,” said Dr. Len Horovitz, a pulmonologist at Lenox Hill Hospital in New York City, who also reviewed the study.

“You may lose interest in eating because everything tastes the same and lose weight without wanting or needing to,” Horovitz said. “It’s important to work with a nutritionist to make sure your body is getting all of the nutrients it needs if you can’t smell.”

More information

The American Academy of Otolaryngology–Head and Neck Surgery Foundation has more about smell loss related to COVID-19.

SOURCES: Lyss Stern, New York City; Jay Piccirillo, MD, professor, Department of Otolaryngology—Head and Neck Surgery, Washington University School of Medicine in St. Louis; Alan Hirsch, MD, neurological director, Smell & Taste Treatment and Research Foundation, Chicago; Len Horovitz, MD, pulmonologist, Lenox Hill Hospital, New York City; JAMA Otolaryngology–Head & Neck Surgery, Nov. 18, 2021

Trucking industry looking for 80,000 drivers to help fix the supply chain

October 26, 2021 – Retirements and industry burnout, coupled with increased consumer demand have left the trucking industry short of 80,000 drivers. That’s a 30% increase from before the pandemic, when the industry already faced a labor shortage of 61,500 drivers, Chris Spear, president and CEO of the American Trucking Associations, told CNN.

The dearth of drivers is yet another factor adding pressure to the U.S. supply chain. President Biden directed the Ports of Los Angeles and Long Beach to move to 24/7 operations, but the ports can’t yet work round the clock because there are not enough drivers to move the cargo at all hours.

“24/7 operations – it’s an improvement,” said Spear. “But it doesn’t matter if it’s a port in LA or Long Beach, or the last mile of delivery from a train to a warehouse in Wichita. You’re going to have to have a driver and a truck move that freight.”

If nothing is done, the latest figures put the industry on track for a shortage of 160,000 drivers by 2030, and the need for 1,000,000 new drivers over the next ten years, according to the American Trucking Associations.

A bipartisan infrastructure bill awaiting action in Congress would authorize hundreds of billions of dollars for transportation, which would include workforce development for the trucking industry. The bill would also allow 3,000 drivers between the ages of 18-20 to undergo training, permitting them to drive tractor-trailers across state lines. Currently, drivers must be 21 to do so.

Learn More

Filed Under: Repertoire’s Dail-eNews

Amazon to roll out Alexa for use in healthcare systems, senior living communities with Alexa Smart Properties

October 25, 2021 – Amazon announced two new solutions for senior living and healthcare providers to integrate Alexa into their properties. Part of Alexa Smart Properties, the solutions were designed specifically for the needs of senior living communities and healthcare facilities.

Several large health systems including Boston Children’s Hospital (Boston, MA), Cedars-Sinai (Los Angeles, CA), BayCare (Tampa, FL), and Houston Methodist (Houston, TX) will deploy the new Alexa capability to select properties, according to the news release.

Hospitals can provide information customized to their facility, like notifications about schedule changes or cafeteria menus, and skill experiences like games, podcasts, and more. Hospitals and senior living communities can also build and enable HIPAA-eligible skills, like medication tracking, to connect care providers with residents and patients in an environment designed to protect their health information.

The company says that Alexa Smart Properties simplifies deploying and managing Alexa-enabled devices at scale, in order to help properties “offer customized Alexa experiences for residents and patients, and increase care team productivity and operational efficiency.”

Through the Amazon Echo device in patient rooms, administrators can offer access to tens of thousands of Alexa skills, and tailor resident experiences by customizing community information like activity schedules and meal menus. Care team members can communicate with residents using Alexa communication features, which enable them to make announcements, voice and video calls, or send direct audio messages to other Alexa-enabled devices throughout the property.

The company says that no personal information is shared with Alexa to use the device, and voice recordings are not saved. And that Amazon implements administrative, technical, and physical safeguards for protected health information received as part of HIPAA-eligible skill interactions.

Alexa Smart Properties will support senior living and healthcare solutions in the U.S. starting next month.

Learn More

Mark Cuban-owned company launches pharmacy-benefit manager

October 25, 2021 – A pair of new pharmacy-benefit management (PBM) companies are being launched to tackle high drug costs – The Mark Cuban Cost Plus Drug Company PBC and the Purchaser Business Group on Health (PBGH), a nonprofit coalition of nearly 40 large public and private employers.

PBGH is led by CEO Elizabeth Mitchell and The Mark Cuban Cost Plus Drug Company PBC is led by radiologist Alex Oshmyansky.

Mark Cuban, the billionaire investor and owner of the Dallas Mavericks, is funding the new company with the aim of selling generic drugs at a transparent fixed-rate markup. To do so, it is creating an all-in-one pharmaceutical supplier, combining manufacturing, wholesale distribution and pharmacy services under one roof.

Cuban’s PBM is building a plant in Dallas to manufacture certain drugs, and hopes to open the facility in September 2022, said CEO Dr. Alex Oshmyansky. The company will start bidding for clients next year and aims to be operational in 2023. Cuban’s company plans to soon launch an online pharmacy that will sell 100 of the most commonly prescribed generic medications. The pharmacy is buying drugs directly from generic manufacturers including Amneal Pharmaceuticals Inc., and will charge customers a 15% markup plus a $3 dispensing fee.

PBGH’s new PBM, EmsanaRx, will be housed under an independent for-profit company called Emsana Health. The PBM will start operating next year with a small number of regional medical centers with about 3,000 employees total, said Chief Executive Greg Baker. It aims to negotiate rebates directly with drugmakers, and will allow its clients to examine invoices showing the dollar amounts it receives in rebates. The PBM intends to share 98.5% to 99% of the rebates with its clients, with the remainder going to cover administrative expenses, said Mr. Baker.

The ultimate aim of the new pharmacy-benefit managers, their executives said, was to be more transparent about drug costs and share with their clients more of any negotiated savings.

The new companies are the result of employer frustration with the lack of transparency and lack of savings from the current PBMs. Transparency in the PBM industry typically means charging a flat fee for services and passing along to the employer 100% of the rebates and discounts paid by drugmakers to the PBM. In theory, PBMs are supposed to pass along these large savings to their customers. In practice, the PBMs failing to disclose all the rebates and keeping too much of the savings some employers say.

According to a Wall Street Journal report, nearly 80% of U.S. prescriptions are managed by three PBMs:

  • CVS Health Corp.’s CVS Caremark
  • Cigna Corp.’s Express Scripts
  • UnitedHealth Group Inc.’s OptumRx

Filed Under: Repertoire’s Dail-eNews

Legislators to consider establishing federal office to manage supply chain crises

Repertoire’s Dail-eNews

October 20, 2021 – With supply chain issues expected to stretch well into next year and beyond, lawmakers are looking to centralize Washington’s response and encourage more companies to bring manufacturing processes closer to home to better protect the U.S. from future catastrophic disruptions.

A bipartisan group of legislators introduced the Supply CHAIN Act earlier this month to create an Office of Supply Chain Resiliency and Crisis Response within the U.S. Department of Commerce to monitor the supply chains of critical goods and respond to disruptions.

With a $500 million annual budget from 2022-2027, the office would bring together private-sector stakeholder groups, monitor critical supply chain issues and present recommendations every four years to improve supply chain security and resiliency.

The proposal follows steps taken by the Biden administration to address supply chain weaknesses exposed by the pandemic, reports Supply Chain Dive. The White House issued a 250-page report outlining goals for reviving domestic production of semiconductors, large capacity batteries, critical minerals and pharmaceuticals amid shortages along every stage of the supply chain.

Cheaper labor in China, India and other countries has long presented inherent barriers to reshoring, and many U.S. companies have limited domestic inventories to maximize profits, said Sanjay L. Ahire, co-director of the Operations and Supply Chain Center at the University of South Carolina’s Darla Moore School of Business.

Ahire told Supply Chain Dive companies are realizing the need to look beyond the “sticker price,” as he called it, to what’s known as the “total cost of ownership,” which includes hidden costs of faraway manufacturing.

The bill will need to go before both the House of Representatives and Senate for a vote.

Federal Judge Rules Religious Exemptions to Vaccine Mandates Must Be Allowed

By Kipp Jones  October 12, 2021 at 10:12am

A federal judge in New York ruled on Tuesday that religious exemptions for health care workers must be upheld in spite of the state’s sweeping COVID-19 vaccine mandate.

Then-Democratic New York Gov. Andrew Cuomo announced the mandate in August.

The governor’s office said on Aug. 16 that “all healthcare workers in New York State, including staff at hospitals and long-term care facilities… including nursing homes, adult care, and other congregate care settings, will be required to be vaccinated against COVID-19 by Monday, September 27.”

When COVID ambushed New York last year, New Yorkers acted, while the Federal Government denied the problem,” Cuomo said at the time. “Now, the Delta variant is spreading across the nation and across New York …”

“Our healthcare heroes led the battle against the virus, and now we need them to lead the battle between the variant and the vaccine.

“I have strongly urged private businesses to implement vaccinated-only admission policies, and school districts to mandate vaccinations for teachers. Neither will occur without the state legally mandating the actions — private businesses will not enforce a vaccine mandate unless it’s the law, and local school districts will be hesitant to make these challenging decisions without legal direction.”

Health care workers filed a lawsuit over the mandate, which led to Tuesday’s ruling that religious exemptions must be allowed, Spectrum News reported.

U.S. District Judge David Hurd of the Northern District of New York, in a 27-page ruling, banned any retaliation by state health officials against health care workers who do not want to be vaccinated due to religious reasons.

“The Department of Health is barred from taking any action, disciplinary or otherwise, against the licensure, certification, residency, admitting privileges or other professional status or qualification of any of the plaintiffs on account of their seeking or having obtained a religious exemption from mandatory COVID-19 vaccination,” Hurd said in his decision.

The ruling also protects companies from facing any punishment from the state for employing unvaccinated health care workers who do receive an exemption.

The lawsuit against the state was led by 17 health anonymous care professionals, WROC-TV reported.

It argued that “[p]laintiffs hold the sincere religious belief that they ‘cannot consent to be inoculated … with vaccines that were tested, developed or produced with fetal cell[ ] line[s] derived from procured abortions.

Melanie Franco, the attorney for the plaintiffs, commented on the lawsuit in September.

“Health care workers could still get medical exemptions, but not religious exemptions. Their arguments are that it goes against not only the constitution but also the New York State Human Rights Law,” Franco said, according to WROC.

The outlet reported that Hurd said he would welcome an appeal to his decision in favor of the state’s health care workers.

“[The ruling has] nothing to do with how an individual employer should handle an individual employee’s religious objection to a workplace vaccination requirement. But they have everything to do with the proper division of federal and state power,” the judge said.

“Because the issues in dispute are of exceptional importance to the health and the religious freedoms of our citizens, an appeal may very well be appropriate,” he said.

Democratic New York Gov. Kathy Hochul was listed as a defendant in the lawsuit, as was state Attorney General Letitia James.